Recognitions
We are honored to be recognized for our accomplishments in the area of stem cell technology and its application.
Innovator of the Year Award 2022
Image
Recognition by DSIR
Image
Patents
Stempeucel® process patent bas been granted in 18 countries including USA, Japan, China, Singapore, Australia, New Zealand, UK, France, Germany, Italy and South Africa
Image
ISO 9001:2015
Stempeutics has been awarded ISO 9001:2015 certification for Development and Manufacturing of Mesenchymal Stromal Cell Based products for commercial use and for clinical trial use.
Commercial Use: For DCGI Approved Indications
Clinical Trial Use: For Chosen Indications: Critical Limb Ischemia (CLI), Osteoarthritis (OA) and Diabetic Foot Ulcer (DFU)
Commercial Use: For DCGI Approved Indications
Clinical Trial Use: For Chosen Indications: Critical Limb Ischemia (CLI), Osteoarthritis (OA) and Diabetic Foot Ulcer (DFU)
Image
ATMP & ODD Status in Europe:
Stempeucel® has been classified as an ATMP product and designated as an Orphan Drug for the treatment of CLI due to Buerger's Disease by EMA
Recognised Nationally by
Image
DSIR
Stempeutics Bangalore and R&D at Kemwell units have been recognised by Department of Scientific and Industrial Research (DSIR), Government of India
Image
DCGI
Stempeutics CTM at Kemwell facility has been approved by DCGI for clinical trial manufacturing (Form 29) as well as for commercial manufacturing (Form 28)
Image
ABLE
BN Manohar is the Chairperson of ABLE (Association of Biotechnology Led Enterprise – India) – Regenerative Medicine sub-committee
Image
COPP
Certificate of a Pharmaceutical Product has been granted by State drug control department
Image
ISCT
Stempeutics has been awarded ISCT 2022 Top Scoring Emerging Economy Abstract Award
